Purpose. To assess the effects of oral vitamin B1 and mecobalamin on dry eye disease (DED) and patient satisfaction with treatment. Methods. In this randomized controlled study, DED patients were divided into 4 groups based on treatment: group 1, only artificial tears; group 2, corticosteroid eye drops and artificial tears; group 3, oral vitamin B1, mecobalamin, and artificial tears; and group 4, oral vitamin B1, mecobalamin, corticosteroid eye drops, and artificial tears. DED symptoms, signs, and patient satisfaction with treatment were assessed at baseline and at 1 and 2 months after treatment. Results. In total, 152 eyes from 76 patients (age, 55.25 ± 18.16 years) were included. In group 3, there were significant differences in dryness, foreign body sensation, burning, and tear film breakup time first (TBUTF) between 1 and 2 months after treatment and in satisfaction scores before and after treatment ( ). In group 3, there were also significant differences in dryness, foreign body sensation, photophobia, and TBUTA and between baseline and 2 months after treatment ( ). There was a significant difference in foreign body sensation between 1 and 2 months after treatment in groups 3 and 4 ( ). Furthermore, we also find obvious improvement in corneal nerve fiber density (CNFD) between baseline and 1 and 2 months after treatment in groups 3 and 4 ( ). Conclusions. Oral vitamin B1 and mecobalamin can relieve some dry eye symptoms such as dryness, pain, and photophobia and improve DED signs and patient satisfaction. Thus, vitamin B1 and mecobalamin are potential treatment options for patients with DED.
In the present study we compared dynamic visual acuity (DVA) of 84 eyes (for 42 adults with myopia; M age = 28.4, SD = 6.6 years; males = 38.1%, females = 61.9%) at 40 and 80 degree per second (dps) before surgery with eyeglass corrections and after a surgical procedure – a small incision lenticule extraction (SMILE). Participants underwent binocular SMILE surgery with plano refraction targets. Their eyeglass-corrected binocular DVA at 40 and 80 dps was evaluated preoperatively, and their uncorrected binocular DVA was assessed post-operatively at 1 week, 1 month and 3 months. The mean logMAR (logarithm of the minimum angle of resolution) uncorrected and corrected distance visual acuities (UDVA and CDVA) were −0.09 and −0.11 respectively, 3 months postoperatively. The mean preoperative eyeglass-corrected DVAs at 40 and 80 dps were 0.141 and 0.184, respectively, and significant improvements were observed for 40 dps and 80 dps DVAs 3 months postoperatively. Pearson’s correlations were statistically significant between the postoperative DVAs at 3 months and for both the preoperative DVA and postoperative UDVA at both 40 dps and 80 dps. The change in the DVAs at 3 months were significantly associated with the preoperative DVAs at 40 dps and 80 dps. In conclusion, myopic patients’ DVAs significantly improved following SMILE in comparison to corrected preoperative visual acuity when wearing eyeglasses. The post-SMILE DVA was associated with both the preoperative DVA and the postoperative UDVA.